Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -28.62% is 100% above its 5-year average of -12451.84%, near the high end of its 5-year range (-234991.30%–0.17%).
47.33% below its 12-month average of -19.43%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -21.50%.
EBITDA MARGIN
-28.62%
EBITDA MARGIN AVG TTM
-19.43%
EBITDA MARGIN AVG 3Y
-5030.51%
EBITDA MARGIN AVG 5Y
-12451.84%
EBITDA MARGIN AVG 10Y
-12762.57%
EBITDA MARGIN AVG 15Y
-9375.51%
EBITDA MARGIN AVG 20Y
-5721.87%
CURRENT VS TTM AVG
-47.33%
CURRENT VS 3Y AVG
+99.43%
CURRENT VS 5Y AVG
+99.77%
CURRENT VS 10Y AVG
+99.78%
CURRENT VS 15Y AVG
+99.69%
CURRENT VS 20Y AVG
+99.50%
Geron Corporation
Market Cap
$776.24M
EBITDA Margin
-28.62%
TTM Avg
-19.43%
3Y Avg
-5030.51%
5Y Avg
-12451.84%
Market Cap
$775.72M
EBITDA Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$774.32M
EBITDA Margin
-4915.19%
TTM Avg
-4915.19%
3Y Avg
-4915.19%
5Y Avg
-4915.19%
Market Cap
$780.95M
EBITDA Margin
18.47%
TTM Avg
18.88%
3Y Avg
13.21%
5Y Avg
14.52%
Market Cap
$767.46M
EBITDA Margin
-123018.64%
TTM Avg
-69257.96%
3Y Avg
-35033.94%
5Y Avg
-23599.85%
Market Cap
$786.48M
EBITDA Margin
-14.10%
TTM Avg
-9.55%
3Y Avg
-6.60%
5Y Avg
-0.48%
Market Cap
$749.55M
EBITDA Margin
-27116.80%
TTM Avg
-23848.80%
3Y Avg
-16467.00%
5Y Avg
-16467.00%
Market Cap
$734.10M
EBITDA Margin
-4821.38%
TTM Avg
-3832.53%
3Y Avg
-2582.73%
5Y Avg
-1806.92%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Geron Corporation (GERN) | $776.24M | -28.62% | -19.43% | -5030.51% | -12451.84% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | -4915.19% | -4915.19% | -4915.19% | -4915.19% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 18.47% | 18.88% | 13.21% | 14.52% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -123018.64% | -69257.96% | -35033.94% | -23599.85% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -14.10% | -9.55% | -6.60% | -0.48% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -27116.80% | -23848.80% | -16467.00% | -16467.00% |
| InMode Ltd. (INMD)vs › | $812.20M | 23.23% | 25.96% | 33.88% | 36.34% |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -4821.38% | -3832.53% | -2582.73% | -1806.92% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | 12.02% | 14.44% | -4.83% | -238.26% |
Gross Margin
97.4%
EBITDA Margin
-28.6%
Operating Margin
-29.3%
Net Margin
-34.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -21.50% |
| 2026-03-31 | 0.17% |
| 2025-12-31 | -21.90% |
| 2025-09-30 | -29.13% |
| 2025-06-30 | -24.77% |
| 2025-03-31 | -41.40% |
| 2024-12-31 | -41.51% |
| 2024-09-30 | -99.09% |
| 2024-06-30 | -7812.24% |
| 2024-03-31 | -18374.67% |
| 2023-12-31 | -234991.30% |
| 2023-09-30 | -28869.51% |
| 2023-06-30 | -178193.10% |
| 2023-03-31 | -189719.05% |
| 2022-12-31 | -40651.46% |
| 2022-09-30 | -13423.91% |
| 2022-06-30 | -38027.40% |
| 2022-03-31 | -23266.67% |
| 2021-12-31 | -2973.17% |
| 2021-09-30 | -23505.50% |
| 2021-06-30 | -26949.53% |
| 2021-03-31 | -20734.31% |
| 2020-12-31 | -46434.00% |
| 2020-09-30 | -18425.00% |
| 2020-06-30 | -38904.65% |
| 2020-03-31 | -32390.38% |
| 2019-12-31 | -17531.58% |
| 2019-09-30 | -12055.73% |
| 2019-06-30 | -14731.68% |
| 2019-03-31 | -19800.00% |
| 2018-12-31 | -2553.33% |
| 2018-09-30 | -4115.76% |
| 2018-06-30 | -3474.52% |
| 2018-03-31 | -2333.65% |
| 2017-12-31 | -4066.49% |
| 2017-09-30 | -4432.52% |
| 2017-06-30 | -3858.05% |
| 2017-03-31 | -1391.81% |
| 2016-12-31 | -9322.34% |
| 2016-09-30 | -75.49% |
| 2016-06-30 | -4213.27% |
| 2016-03-31 | -1209.08% |
| 2015-12-31 | -3921.36% |
| 2015-09-30 | 76.46% |
| 2015-06-30 | -3771.31% |
| 2015-03-31 | -1759.22% |
| 2014-12-31 | -5057.30% |
| 2014-09-30 | -6186.25% |
| 2014-06-30 | -2536.36% |
| 2014-03-31 | -1838.82% |
| 2013-09-30 | -4773.48% |
| 2013-06-30 | -7895.54% |
| 2013-03-31 | -1548.10% |
| 2012-12-31 | -2657.76% |
| 2012-09-30 | -2466.04% |
| 2012-06-30 | -14050.00% |
| 2012-03-31 | -1488.60% |
| 2011-12-31 | -11977.69% |
| 2011-09-30 | -8879.09% |
| 2011-06-30 | -4545.45% |
| 2011-03-31 | -1590.56% |
| 2010-12-31 | -5392.53% |
| 2010-09-30 | -3259.89% |
| 2010-06-30 | -1645.25% |
| 2010-03-31 | -1751.63% |
| 2009-12-31 | -2969.42% |
| 2009-09-30 | -3226.32% |
| 2009-06-30 | -10071.58% |
| 2009-03-31 | -3636.71% |
| 2008-12-31 | -4023.90% |
| 2008-09-30 | -4823.16% |
| 2008-06-30 | -7467.17% |
| 2008-03-31 | -900.00% |
| 2007-12-31 | -292.75% |
| 2007-09-30 | -1306.81% |
| 2007-06-30 | -1837.68% |
| 2007-03-31 | -1755.90% |
| 2006-12-31 | -1072.41% |
| 2006-09-30 | -1632.64% |
| 2006-06-30 | -1411.32% |
| 2006-03-31 | -1743.74% |
| 2005-12-31 | 189.77% |
| 2005-09-30 | -1803.57% |
| 2005-06-30 | -60.57% |
| 2005-03-31 | -15757.63% |
| 2004-09-30 | -8776.24% |
| 2004-06-30 | -2007.65% |
| 2004-03-31 | -20187.90% |
| 2003-12-31 | -4625.81% |
| 2003-09-30 | -895.13% |
| 2003-06-30 | -2683.51% |
| 2003-03-31 | -19486.11% |
| 2002-12-31 | -1439.59% |
| 2002-09-30 | -3218.81% |
